company background image
503

Lansen Pharmaceutical HoldingsSEHK:503 Stock Report

Market Cap

HK$552.8m

7D

9.6%

1Y

94.7%

Updated

27 Sep, 2021

Data

Company Financials
503 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

503 Overview

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Lansen Pharmaceutical Holdings
Historical stock prices
Current Share PriceHK$1.48
52 Week HighHK$0.71
52 Week LowHK$4.15
Beta1.48
1 Month Change-33.63%
3 Month Change-42.19%
1 Year Change94.74%
3 Year Change43.69%
5 Year Change-22.51%
Change since IPO-67.54%

Recent News & Updates

Sep 04
Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

Is Lansen Pharmaceutical Holdings (HKG:503) A Risky Investment?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Shareholder Returns

503HK PharmaceuticalsHK Market
7D9.6%-2.6%-2.4%
1Y94.7%-12.0%9.1%

Return vs Industry: 503 exceeded the Hong Kong Pharmaceuticals industry which returned -12% over the past year.

Return vs Market: 503 exceeded the Hong Kong Market which returned 9.1% over the past year.

Price Volatility

Is 503's price volatile compared to industry and market?
503 volatility
503 Beta1.48
Industry Beta0.59
Market Beta1

Stable Share Price: 503 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 25% a week.

Volatility Over Time: 503's weekly volatility has increased from 15% to 25% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001627Li Chenhttps://www.lansen.com.cn

Lansen Pharmaceutical Holdings Limited, an investment holding company, develops, produces, and sells specialty pharmaceuticals for use in the field of rheumatology and dermatology in the People’s Republic of China and internationally. It operates through Pharmaceuticals, Cosmetics Products, and Healthcare Products segments. The company offers specialist medicines and Chinese medicine generic drugs; cosmetic products; and plant extracts and healthcare products.

Lansen Pharmaceutical Holdings Fundamentals Summary

How do Lansen Pharmaceutical Holdings's earnings and revenue compare to its market cap?
503 fundamental statistics
Market CapUS$71.01m
Earnings (TTM)-US$6.71m
Revenue (TTM)US$51.10m

1.4x

P/S Ratio

-10.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
503 income statement (TTM)
RevenueUS$51.10m
Cost of RevenueUS$18.70m
Gross ProfitUS$32.40m
ExpensesUS$39.11m
Earnings-US$6.71m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.018
Gross Margin63.41%
Net Profit Margin-13.13%
Debt/Equity Ratio14.7%

How did 503 perform over the long term?

See historical performance and comparison

Valuation

Is Lansen Pharmaceutical Holdings undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 503 (HK$1.48) is trading below our estimate of fair value (HK$8.64)

Significantly Below Fair Value: 503 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 503 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Pharmaceuticals industry average.

PE vs Market: 503 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 503's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 503 is good value based on its PB Ratio (0.4x) compared to the HK Pharmaceuticals industry average (1.1x).


Future Growth

How is Lansen Pharmaceutical Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lansen Pharmaceutical Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Lansen Pharmaceutical Holdings performed over the past 5 years?

46.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 503 is currently unprofitable.

Growing Profit Margin: 503 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 503 is unprofitable, but has reduced losses over the past 5 years at a rate of 46.9% per year.

Accelerating Growth: Unable to compare 503's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 503 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.8%).


Return on Equity

High ROE: 503 has a negative Return on Equity (-3.38%), as it is currently unprofitable.


Financial Health

How is Lansen Pharmaceutical Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: 503's short term assets ($191.5M) exceed its short term liabilities ($52.0M).

Long Term Liabilities: 503's short term assets ($191.5M) exceed its long term liabilities ($2.5M).


Debt to Equity History and Analysis

Debt Level: 503's debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: 503's debt to equity ratio has reduced from 103.3% to 14.7% over the past 5 years.

Debt Coverage: 503's debt is well covered by operating cash flow (54.9%).

Interest Coverage: 503's interest payments on its debt are well covered by EBIT (37.7x coverage).


Balance Sheet


Dividend

What is Lansen Pharmaceutical Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 503's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 503's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 503's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 503's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 503 is not paying a notable dividend for the Hong Kong market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 503's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average board tenure


CEO

Li Chen (59 yo)

3.5yrs

Tenure

US$624,000

Compensation

Mr. Li Chen has been Chief Executive Officer and Executive Managing Director of Lansen Pharmaceutical Holdings Ltd since March 1, 2018. He has been General Manager in Alfa Wassermann China since July 2014....


CEO Compensation Analysis

Compensation vs Market: Li's total compensation ($USD624.00K) is above average for companies of similar size in the Hong Kong market ($USD229.36K).

Compensation vs Earnings: Li's compensation has been consistent with company performance over the past year.


Board Members

Experienced Board: 503's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Lansen Pharmaceutical Holdings Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Lansen Pharmaceutical Holdings Limited
  • Ticker: 503
  • Exchange: SEHK
  • Founded: 2001
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$552.813m
  • Shares outstanding: 373.52m
  • Website: https://www.lansen.com.cn

Number of Employees


Location

  • Lansen Pharmaceutical Holdings Limited
  • 228 Xinfeng Road
  • Gaoqiao Industrial Park
  • Ningbo
  • Zhejiang Province
  • 315174
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/27 15:44
End of Day Share Price2021/09/27 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.